Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

INTRODUCTION: Anti-PD-1 therapies, pembrolizumab and nivolumab, are currently the standard of care for treatment of patients with metastatic melanoma. Treatment is usually continued until toxicity or disease progression. Though these therapies are well tolerated, some patients discontinue them due t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Oncol
Main Authors: Swami, Umang, Monga, Varun, Bossler, Aaron D., Zakharia, Yousef, Milhem, Mohammed
Format: Artigo
Jezik:Inglês
Izdano: Hindawi 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6683789/
https://ncbi.nlm.nih.gov/pubmed/31428149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/1856594
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki